Literature DB >> 32797191

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy.

Bicky Thapa1, Paolo F Caimi2, Kirit M Ardeshna3, Melhem Solh4, Carmelo Carlo-Stella5, Brad S Kahl6, Mehdi Hamadani1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32797191      PMCID： PMC7448593          DOI： 10.1182/bloodadvances.2020002587

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  10 in total

1.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

Review 2.  Management of relapsed/refractory DLBCL.

Authors:  Clémentine Sarkozy; Laurie H Sehn
Journal:  Best Pract Res Clin Haematol       Date:  2018-07-23       Impact factor: 3.020

Review 3.  Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Authors:  Tania Jain; Merav Bar; Ankit J Kansagra; Elise A Chong; Shahrukh K Hashmi; Sattva S Neelapu; Michael Byrne; Elad Jacoby; Aleksandr Lazaryan; Caron A Jacobson; Stephen M Ansell; Farrukh T Awan; Linda Burns; Veronika Bachanova; Catherine M Bollard; Paul A Carpenter; John F DiPersio; Mehdi Hamadani; Helen E Heslop; Joshua A Hill; Krishna V Komanduri; Craig A Kovitz; Hillard M Lazarus; Justin M Serrette; Mohamad Mohty; David Miklos; Arnon Nagler; Steven Z Pavletic; Bipin N Savani; Stephen J Schuster; Mohamed A Kharfan-Dabaja; Miguel-Angel Perales; Yi Lin
Journal:  Biol Blood Marrow Transplant       Date:  2019-08-22       Impact factor: 5.742

4.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

5.  ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.

Authors:  Francesca Zammarchi; Simon Corbett; Lauren Adams; Peter C Tyrer; Konstantinos Kiakos; Narinder Janghra; Teresa Marafioti; Charles E Britten; Carin E G Havenith; Simon Chivers; Francois D'Hooge; David G Williams; Arnaud Tiberghien; Philip W Howard; John A Hartley; Patrick H van Berkel
Journal:  Blood       Date:  2018-01-03       Impact factor: 22.113

6.  A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

Authors:  Brad S Kahl; Mehdi Hamadani; John Radford; Carmelo Carlo-Stella; Paolo Caimi; Erin Reid; Jay M Feingold; Kirit M Ardeshna; Melhem Solh; Leonard T Heffner; David Ungar; Shui He; Joseph Boni; Karin Havenith; Owen A O'Connor
Journal:  Clin Cancer Res       Date:  2019-11-04       Impact factor: 12.531

Review 7.  CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.

Authors:  R H Scheuermann; E Racila
Journal:  Leuk Lymphoma       Date:  1995-08

8.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

9.  Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.

Authors:  Mehdi Hamadani; Parameswaran N Hari; Ying Zhang; Jeanette Carreras; Görgün Akpek; Mahmoud D Aljurf; Ernesto Ayala; Veronika Bachanova; Andy I Chen; Yi-Bin Chen; Luciano J Costa; Timothy S Fenske; César O Freytes; Siddhartha Ganguly; Mark S Hertzberg; Leona A Holmberg; David J Inwards; Rammurti T Kamble; Edward J Kanfer; Hillard M Lazarus; David I Marks; Taiga Nishihori; Richard Olsson; Nishitha M Reddy; David A Rizzieri; Bipin N Savani; Melhem Solh; Julie M Vose; Baldeep Wirk; David G Maloney; Sonali M Smith; Silvia Montoto; Wael Saber; Onder Alpdogan; Amanda Cashen; Christopher Dandoy; Robert Finke; Robert Gale; John Gibson; Jack W Hsu; Nalini Janakiraman; Mary J Laughlin; Michael Lill; Mitchell S Cairo; Reinhold Munker; Phil A Rowlings; Harry C Schouten; Thomas C Shea; Patrick J Stiff; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-05       Impact factor: 5.742

10.  Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Authors:  W Jurczak; P L Zinzani; G Gaidano; A Goy; M Provencio; Z Nagy; T Robak; K Maddocks; C Buske; S Ambarkhane; M Winderlich; M Dirnberger-Hertweck; R Korolkiewicz; K A Blum
Journal:  Ann Oncol       Date:  2018-05-01       Impact factor: 32.976
  10 in total
  7 in total

Review 1.  Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.

Authors:  Leila Amini; Sara K Silbert; Nirali N Shah; Mohamed Abou-El-Enein; Shannon L Maude; Loretta J Nastoupil; Carlos A Ramos; Renier J Brentjens; Craig S Sauter
Journal:  Nat Rev Clin Oncol       Date:  2022-03-22       Impact factor: 66.675

Review 2.  Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab.

Authors:  Sotirios G Papageorgiou; Thomas P Thomopoulos; Athanasios Liaskas; Theodoros P Vassilakopoulos
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

Review 3.  Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.

Authors:  Jérôme Paillassa; Firas Safa
Journal:  Leuk Res Rep       Date:  2021-12-10

Review 4.  Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data.

Authors:  Fateeha Furqan; Mehdi Hamadani
Journal:  Ther Adv Hematol       Date:  2022-03-22

Review 5.  CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma.

Authors:  Massimiliano Gambella; Simona Carlomagno; Anna Maria Raiola; Livia Giannoni; Chiara Ghiggi; Chiara Setti; Chiara Giordano; Silvia Luchetti; Alberto Serio; Alessandra Bo; Michela Falco; Mariella Della Chiesa; Emanuele Angelucci; Simona Sivori
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

6.  Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.

Authors:  Mehdi Hamadani; John Radford; Carmelo Carlo-Stella; Paolo F Caimi; Erin Reid; Owen A O'Connor; Jay M Feingold; Kirit M Ardeshna; William Townsend; Melhem Solh; Leonard T Heffner; David Ungar; Luqiang Wang; Joseph Boni; Karin Havenith; Yajuan Qin; Brad S Kahl
Journal:  Blood       Date:  2021-05-13       Impact factor: 22.113

Review 7.  Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies.

Authors:  Yazeed Sawalha
Journal:  J Pers Med       Date:  2021-12-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.